Home » Stocks » CALT

Calliditas Therapeutics AB (CALT)

Stock Price: $30.10 USD -1.03 (-3.31%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 762.59M
Revenue (ttm) 19.87M
Net Income (ttm) -3.50M
Shares Out 46.30M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $30.10
Previous Close $31.13
Change ($) -1.03
Change (%) -3.31%
Day's Open 30.84
Day's Range 30.10 - 30.56
Day's Volume 1,177
52-Week Range 19.17 - 36.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed i...

Seeking Alpha - 2 months ago

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...

Other stocks mentioned: BGNE, BNTX, IMAB, MRK, PFE, TMO
PRNewsWire - 2 months ago

STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas w...

PRNewsWire - 2 months ago

STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the eff...

PRNewsWire - 2 months ago

STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced positive topline results from Part A of the global Phase 3 ...

PRNewsWire - 3 months ago

STOCKHOLM, Sept. 30, 2020 /PRNewswire/ -- During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company's warrant program issued in 2017. Thus, as o...

PRNewsWire - 5 months ago

Successful capital raise on NASDAQ STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- "In June we successfully closed a $90m U.S.

PRNewsWire - 5 months ago

STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020.

Benzinga - 6 months ago

Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.

About CALT

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephro... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 5, 2020
CEO
Renee Aguiar-Lucander
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
CALT
Full Company Profile

Financial Performance

Financial numbers in millions SEK.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CALT is 48.00, which is an increase of 59.47% from the latest price.

Price Target
$48.00
(59.47% upside)